186 related articles for article (PubMed ID: 35021602)
1. Clinical relevance of proteomic profiling in
Hoff FW; Van Dijk AD; Qiu Y; Hu CW; Ries RE; Ligeralde A; Jenkins GN; Gerbing RB; Gamis AS; Aplenc R; Kolb EA; Alonzo TA; Meshinchi S; Qutub AA; De Bont ESJM; Horton TM; Kornblau SM
Haematologica; 2022 Oct; 107(10):2329-2343. PubMed ID: 35021602
[TBL] [Abstract][Full Text] [Related]
2. Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.
Hoff FW; van Dijk AD; Qiu Y; Ruvolo PP; Gerbing RB; Leonti AR; Jenkins GN; Gamis AS; Aplenc R; Kolb EA; Alonzo TA; Meshinchi S; de Bont ESJM; Bruggeman SWM; Kornblau SM; Horton TM
Blood; 2021 Feb; 137(8):1050-1060. PubMed ID: 32959058
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA.
van Dijk AD; Hoff FW; Qiu Y; Gerbing RB; Gamis AS; Aplenc R; Kolb EA; Alonzo TA; Meshinchi S; Jenkins GN; de Bont ESJM; Kornblau SM; Horton TM
Proteomics Clin Appl; 2022 Mar; 16(2):e2100072. PubMed ID: 34719869
[TBL] [Abstract][Full Text] [Related]
4. Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia.
van Dijk AD; Hoff FW; Qiu YH; Chandra J; Jabbour E; de Bont ESJM; Horton TM; Kornblau SM
Clin Epigenetics; 2021 Jan; 13(1):21. PubMed ID: 33509276
[TBL] [Abstract][Full Text] [Related]
5. Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse.
Hoff FW; Hu CW; Qutub AA; Qiu Y; Hornbaker MJ; Bueso-Ramos C; Abbas HA; Post SM; de Bont ESJM; Kornblau SM
Proteomics Clin Appl; 2019 Jul; 13(4):e1800133. PubMed ID: 30650251
[TBL] [Abstract][Full Text] [Related]
6. DNA Damage Response-Related Proteins Are Prognostic for Outcome in Both Adult and Pediatric Acute Myelogenous Leukemia Patients: Samples from Adults and from Children Enrolled in a Children's Oncology Group Study.
Hubner SE; de Camargo Magalhães ES; Hoff FW; Brown BD; Qiu Y; Horton TM; Kornblau SM
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982970
[TBL] [Abstract][Full Text] [Related]
7. Functional proteomic profiling of AML predicts response and survival.
Kornblau SM; Tibes R; Qiu YH; Chen W; Kantarjian HM; Andreeff M; Coombes KR; Mills GB
Blood; 2009 Jan; 113(1):154-64. PubMed ID: 18840713
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis of childhood de novo acute myeloid leukemia and myelodysplastic syndrome/AML: correlation to molecular and cytogenetic analyses.
Braoudaki M; Tzortzatou-Stathopoulou F; Anagnostopoulos AK; Papathanassiou C; Vougas K; Karamolegou K; Tsangaris GT
Amino Acids; 2011 Mar; 40(3):943-51. PubMed ID: 20711619
[TBL] [Abstract][Full Text] [Related]
9. Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group.
Hoff FW; Griffen TL; Brown BD; Horton TM; Burger J; Wierda W; Hubner SE; Qiu Y; Kornblau SM
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982537
[TBL] [Abstract][Full Text] [Related]
10. Recognition of Recurrent Protein Expression Patterns in Pediatric Acute Myeloid Leukemia Identified New Therapeutic Targets.
Hoff FW; Hu CW; Qiu Y; Ligeralde A; Yoo SY; Mahmud H; de Bont ESJM; Qutub AA; Horton TM; Kornblau SM
Mol Cancer Res; 2018 Aug; 16(8):1275-1286. PubMed ID: 29669821
[TBL] [Abstract][Full Text] [Related]
11. Construction of protein profile classification model and screening of proteomic signature of acute leukemia.
Xu Y; Zhuo J; Duan Y; Shi B; Chen X; Zhang X; Xiao L; Lou J; Huang R; Zhang Q; Du X; Li M; Wang D; Shi D
Int J Clin Exp Pathol; 2014; 7(9):5569-81. PubMed ID: 25337199
[TBL] [Abstract][Full Text] [Related]
12. A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia.
Hu CW; Qiu Y; Ligeralde A; Raybon AY; Yoo SY; Coombes KR; Qutub AA; Kornblau SM
Nat Biomed Eng; 2019 Nov; 3(11):889-901. PubMed ID: 30988472
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective.
van Dijk AD; de Bont ESJM; Kornblau SM
Expert Rev Proteomics; 2020 Jan; 17(1):1-10. PubMed ID: 31945303
[No Abstract] [Full Text] [Related]
14. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
Leith CP; Kopecky KJ; Godwin J; McConnell T; Slovak ML; Chen IM; Head DR; Appelbaum FR; Willman CL
Blood; 1997 May; 89(9):3323-9. PubMed ID: 9129038
[TBL] [Abstract][Full Text] [Related]
15. Network analysis of reverse phase protein expression data: characterizing protein signatures in acute myeloid leukemia cytogenetic categories t(8;21) and inv(16).
York H; Kornblau SM; Qutub AA
Proteomics; 2012 Jul; 12(13):2084-93. PubMed ID: 22623292
[TBL] [Abstract][Full Text] [Related]
16. Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial.
van Dijk AD; Hoff FW; Qiu Y; Hubner SE; Go RL; Ruvolo VR; Leonti AR; Gerbing RB; Gamis AS; Aplenc R; Kolb EA; Alonzo TA; Meshinchi S; de Bont ESJM; Horton TM; Kornblau SM
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672531
[TBL] [Abstract][Full Text] [Related]
17. A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia.
Sloan CE; Luskin MR; Boccuti AM; Sehgal AR; Zhao J; Daber RD; Morrissette JJ; Luger SM; Bagg A; Gimotty PA; Carroll M
PLoS One; 2016; 11(4):e0153016. PubMed ID: 27050425
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of miR-29a expression in pediatric acute myeloid leukemia.
Zhu C; Wang Y; Kuai W; Sun X; Chen H; Hong Z
Clin Biochem; 2013 Jan; 46(1-2):49-53. PubMed ID: 22981932
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
20. Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34
Wang YY; Chen WL; Weng XQ; Sheng Y; Wu J; Hao J; Liu ZY; Zhu YM; Chen B; Xiong SM; Chen Y; Chen QS; Sun HP; Li JM; Wang J
Stem Cells Dev; 2017 Oct; 26(20):1460-1467. PubMed ID: 28810819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
